Background: On January 30, 2020 the COVID-19 pandemic was declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization. Almost a month later on February 29, 2020, the first case in New York City (NYC) was diagnosed. Methods: Three-hundred-sixty persons with COVID-like illness was reported to the NYC Department of Health and Mental Hygiene (DOHMH) before February 29, but 37 of these tested negative and 237 were never tested for SARS-COV-2. Records of 86 persons with confirmed COVID-19 and symptom onset prior to February 29, 2020 were reviewed by four physician-epidemiologists. Case-patients were classified as likely early onset COVID-19, or insufficient evidence to determine onset. Clinical and epidemiological factors collected by DOHMH and supplemented with emergency department records were analyzed. Results: Thirty-nine likely early onset COVID-19 cases were identified. The majority had severe disease with 69% presenting to an ED visit within 2 weeks of symptom onset. The first likely COVID-19 case on record had symptom onset on January 28, 2020. Only 7 of the 39 cases (18%) had traveled internationally within 14 days of onset (none to China). Conclusions: SARS-CoV-2 and COVID-19 was in NYC before being classified as a PHEIC, and eluded surveillance for another month. The delay in recognition limited mitigation effort and by the time that city and state-wide mandates were enacted 16 and 22 days later there was already community transmission.
Hong Kong reported 12,631 confirmed COVID-19 cases and 213 deaths in the first two years of the pandemic but experienced a major wave predominantly of Omicron BA.2.2 in early 2022 with over 1.1 million reported SARS-CoV-2 infections and more than 7900 deaths. Our data indicated a shorter incubation period, serial interval, and generation time of infections with Omicron than other SARS-CoV-2 variants. Omicron BA.2.2 cases without a complete primary vaccination series appeared to face a similar fatality risk to those infected in earlier waves with the ancestral strain.
The Omicron variant of SARS-CoV-2 (B.1.1.529), first identified during November 2021, is rapidly spreading throughout the world, replacing the previously dominant Delta variant. Omicron has a high number of mutations in the spike gene, some of which are associated with greatly increased transmissibility and immune evasion. The BA.1 sublineage has been most prevalent but there is recent evidence that the BA.2 sublineage is increasing in proportion in many countries. Genome sequencing is the gold standard for Omicron identification but is relatively slow, resource intensive, of limited capacity and often unavailable. We therefore developed a simple, rapid reverse transcription PCR (RT-PCR) method for sensitive and specific detection of the Omicron variant, including both the BA.1 and BA.2 sublineages. The assay targets a total of 5 nucleotide mutations in the receptor binding domain of the spike gene that give rise to 4 amino acid substitutions at G339D, S371L, S373P and S375F. The forward primer was designed as a double-mismatch allele specific primer (DMAS) with an additional artificial mismatch located four nucleotides from the 3′ end to enhance binding specificity. Assay specificity was confirmed by testing a wide range of previously-sequenced culture-derived viral isolates and clinical samples including the Alpha, Beta and Delta variants and ′wild type′ SARS-CoV-2. Respiratory syncytial virus and influenza A were also tested. The assay can be run in singleplex format, or alternatively as a multiplex RT-PCR to enable Omicron and Delta variants to be detected and distinguished within the same reaction by means of probes labelled with different fluorescent dyes. Sublineages BA.1 and BA.2 can be differentiated if required. The methods presented here can readily be established in any PCR laboratory and should provide valuable support for epidemiologic surveillance of Omicron infections, particularly in those regions that lack extensive sequencing facilities.
Background: There are presently conflicting data about level and duration of antibodies to SARS-CoV-2 in children after symptomatic or asymptomatic infection. Methods: We enrolled adults and children in a prospective 6-month study in the following categories: 1) symptomatic, SARS-CoV-2 PCR+ (SP+; children, n=8; adults, n=16),
Objective: When novel diseases such as COVID-19 emerge, predictors of clinical outcomes might be unknown. Using data from electronic medical records (EMR) allows evaluation of potential predictors without selecting specific features a priori for a model. We evaluated different machine learning models for predicting outcomes among COVID-19 inpatients using raw EMR data. Materials and Methods: In Premier Healthcare Data Special Release: COVID-19 Edition (PHD-SR COVID-19, release date March, 24 2021), we included patients admitted with COVID-19 during February 2020 through April 2021 and built time-ordered medical histories. Setting the prediction horizon at 24 hours into the first COVID-19 inpatient visit, we aimed to predict intensive care unit (ICU) admission , hyperinflammatory syndrome (HS), and death. We evaluated the following models: L2-penalized logistic regression, random forest, gradient boosting classifier, deep averaging network, and recurrent neural network with a long short-term memory cell. Results: There were 57,355 COVID-19 patients identified in PHD-SR COVID-19. ICU admission was the easiest outcome to predict (best AUC=79%), and HS was the hardest to predict (best AUC=70%). Models performed similarly within each outcome. Discussion: Although the models learned to attend to meaningful clinical information, they performed similarly, suggesting performance limitations are inherent to the data. Conclusion: Predictive models using raw EMR data are promising because they can use many observations and encompass a large feature space; however, traditional and deep learning models may perform similarly when few features are available at the individual patient level.
The COVID-19 pandemic has impacted communities far and wide and put tremendous pressure on healthcare systems of countries across the globe. Understanding and monitoring the major influences on COVID-19 prevalence is essential to inform policy making and device appropriate packages of non-pharmaceutical interventions (NPIs). This study evaluates community level influences on COVID-19 incidence in England and their variations over time with specific focus on understanding the impact of working in so called high-risk industries such as care homes and warehouses. Analysis at community level allows accounting for interrelations between socioeconomic and demographic profile, land use, and mobility patterns including residents9 self-selection and spatial sorting (where residents choose their residential locations based on their travel attitudes and preferences or social structure and inequality); this also helps understand the impact of policy interventions on distinct communities and areas given potential variations in their mobility, vaccination rates, behavioural responses, and health inequalities. Moreover, community level analysis can feed into more detailed epidemiological and individual models through tailoring and directing policy questions for further investigation. We have assembled a large set of static (socioeconomic and demographic profile and land use characteristics) and dynamic (mobility indicators, COVID-19 cases and COVID-19 vaccination uptake in real time) data for small area statistical geographies (Lower Layer Super Output Areas, LSOA) in England making the dataset, arguably, the most comprehensive set assembled in the UK for community level analysis of COVID-19 infection. The data are integrated from a wider range of sources including telecommunications companies, test and trace data, national travel survey, Census and Mid-Year estimates. To tackle methodological challenges specifically accounting for highly interrelated influences, we have augmented different statistical and machine learning techniques. We have adopted a two-stage modelling framework: a) Latent Cluster Analysis (LCA) to classify the country into distinct land use and travel patterns, and b) multivariate linear regression to evaluate influences at each distinct travel cluster. We have also segmented our data into different time periods based on changes in policies and evolvement in the course of pandemic (such as the emergence of a new variant of the virus). By segmenting and comparing influences across spaces and time, we examine more homogeneous behaviour and uniform distribution of infection risks which in turn increase the potential to make causal inferences and help understand variations across communities and over time. Our findings suggest that there exist significant spatial variations in risk influences with some being more consistent and persistent over time. Specifically, the analysis of industrial sectors shows that communities of workers in care homes and warehouses and to a lesser extent textile and ready meal industries tend to carry a higher risk of infection across all spatial clusters and over the whole period we modelled in this study. This demonstrates the key role that workplace risk has to play in COVID-19 risk of outbreak after accounting for the characteristics of workers9 residential area (including socioeconomic and demographic profile and land use features), vaccination rate, and mobility patterns.
Randomized Controlled Clinical Trial to Evaluate The Efficacy and Safety of Healthtone as Prophylaxis for COVID-19 - Condition: COVID-19
Intervention: Dietary Supplement: Rhea® Health Tone
Sponsor: Indonesia University
Completed
Functional Capacity in Patients Post Mild COVID-19 - Condition: COVID-19
Intervention: Device: Cardiopulmonary exercise test (CPET)
Sponsor: Rambam Health Care Campus
Recruiting
Circuit Training Program in Post COVID-19 Patients - Condition: COVID-19
Interventions: Other: Circuit Training Exercise Program; Other: Aerobic Training Exercise Program
Sponsor: Riphah International University
Not yet recruiting
The Effect of Home-based Rehabilitation Program After COVID-19 Infection - Condition: COVID-19
Interventions: Behavioral: Add-on telerehabilitation and home-based rehabilitation; Behavioral: Home-based rehabilitation alone
Sponsor:
National Taiwan University Hospital
Recruiting
Efficacy, Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine - Condition: COVID-19
Interventions: Biological: SARS-CoV-2 protein subunit recombinant vaccine; Biological: placebo
Sponsors: PT Bio Farma; Faculty of Medicine, Universitas Indonesia, Jakarta; Faculty of Medicine, Diponegoro University, Semarang; Faculty of Medicine, Universitas Andalas, Padang; Faculty of Medicine, Universitas Hassanudin, Makassar
Not yet recruiting
Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years. - Condition: COVID-19
Interventions: Biological: 1 Nebulized inhalation for booster groups; Biological: 2 Nebulized inhalation for booster groups; Biological: 3 Nebulized inhalation for booster groups; Biological: 4 Nebulized inhalation for booster groups; Biological: 5 Intramuscular injection for booster groups; Biological: 6 Intramuscular injection for booster groups; Biological: 7 Intramuscular injection for booster groups; Biological: 8 Intramuscular injection for booster groups; Biological: 9 Intramuscular injection for booster groups; Biological: 10 Intramuscular injection for booster groups; Biological: 11 Nebulized inhalation for booster groups; Biological: 12 Nebulized inhalation for booster groups; Biological: 13 Nebulized inhalation for booster groups; Biological: 14 Nebulized inhalation for booster groups; Biological: 15 Intramuscular injection for booster groups; Biological: 16 Intramuscular injection for booster groups; Biological: 17 Intramuscular injection for booster groups; Biological: 18 Intramuscular injection for booster groups; Biological: 19 Intramuscular injection for booster groups; Biological: 20 Intramuscular injection for booster groups; Biological: 21 Nebulized inhalation for primary groups; Biological: 22 Nebulized inhalation for primary groups; Biological: 23 Nebulized inhalation for primary groups; Biological: 24 Nebulized inhalation for primary groups
Sponsor:
Seventh Medical Center of PLA General Hospital
Not yet recruiting
Safety and Efficacy of Enoxaparin and Hydroxychloroquine in COVID-19 - Condition: COVID-19 Pandemic
Intervention: Drug: Enoxaparin, Hydroxychloroquine
Sponsor: Beni-Suef University
Completed
Clinical Evaluation of Rapid RNA Test for Covid-19 - Condition: COVID-19
Intervention: Diagnostic Test: rapid RT-LAMP test to detect SARS-COV-2 RNA
Sponsors: University of Southampton; West Hertfordshire Hospitals NHS Trust; University of Oxford
Completed
Non-inferiority Trial on Treatments in Early COVID-19 - Condition: COVID-19
Interventions: Drug: Sotrovimab; Drug: Tixagevimab Cilgavimab; Drug: Nirmatrelvir Ritonavir
Sponsors: Azienda Ospedaliera Universitaria Integrata Verona; Agenzia Italiana del Farmaco; Azienda Sanitaria-Universitaria Integrata di Udine
Recruiting
Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV) - Condition: COVID-19
Interventions: Biological: Recombinant two-component COVID-19 vaccine (CHO cell); Biological: COVID-19 Vaccine (Vero Cell), Inactivated
Sponsor: Jiangsu Rec- Biotechnology Co., Ltd.
Not yet recruiting
Immunogenicity,Safety and Cross - Immune Response With the Strains of the Booster Immunization Using an Inactivated COVID-19 Vaccine - Condition: COVID-19
Intervention: Biological: Inactivated COVID-19 Vaccine
Sponsor: Sinovac Research and Development Co., Ltd.
Not yet recruiting
A Study to Evaluate the Effectiveness and Safety of SCTV01E (a Recombinant Protein COVID-19 Vaccine) in Population Aged ≥12 Years - Conditions: COVID-19; SARS-CoV-2 Infection
Interventions: Biological: SCTV01E; Biological: CoronaVac; Biological: Sinopharm inactivated COVID-19 vaccine; Biological: other approved COVID-19 vaccines
Sponsor: Sinocelltech Ltd.
Not yet recruiting
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years - Conditions: COVID-19; SARS-CoV-2 Infection
Interventions: Biological: SCTV01C; Biological: SCTV01E; Biological: mRNA vaccine manufactured by Pfizer or Moderna; Biological: Sinopharm inactivated COVID-19 vaccine
Sponsor: Sinocelltech Ltd.
Not yet recruiting
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines - Conditions: COVID-19; SARS-CoV-2 Infection
Interventions: Biological: SCTV01C; Biological: SCTV01E; Biological: Sinopharm inactivated COVID-19 vaccine; Biological: mRNA-1273
Sponsor: Sinocelltech Ltd.
Not yet recruiting
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years - Conditions: SARS-CoV-2 Infection; COVID-19
Interventions: Biological: SCTV01E; Biological: Comirnaty
Sponsor: Sinocelltech Ltd.
Not yet recruiting
Colonization of nasal cavities by Staphylococcus epidermidis mitigates SARS-CoV-2 nucleocapsid phosphoprotein- induced interleukin (IL)-6 in the lung - Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can trigger excessive interleukin (IL)-6 signalling, leading to a myriad of biological effects including a cytokine storm that contributes to multiple organ failure in severe coronavirus disease 2019 (COVID-19). Using a mouse model, we demonstrated that nasal inoculation of nucleocapsid phosphoprotein (NPP) of SARS-CoV-2 increased IL-6 content in bronchoalveolar lavage fluid (BALF). Nasal administration of liquid…
Food phytochemicals, epigallocatechin gallate and myricetin, covalently bind to the active site of the coronavirus main protease in vitro - SARS-CoV-2 main protease is a possible target for protection against viral infection. This study examined the inhibitory effect of food phytochemicals on the main protease of SARS-CoV-2 by determining a cleaved product after chromatographic separation. First, 37 phytochemicals, including glycosides and metabolites, were screened at 20 µM; epigallocatechin gallate, myricetin, theaflavin, herbacetin, piceatannol, myricitrin, and isothiocyanates inhibited the enzyme in varying degrees. The IC(50)…
Mitoxantrone dihydrochloride, an FDA approved drug, binds with SARS-CoV-2 NSP1 C-terminal - One of the major virulence factors of SARS-CoV-2, NSP1, is a vital drug target due to its role in host immune evasion through multiple pathways. NSP1 protein is associated with inhibiting host mRNA translation by binding to the small subunit of ribosome through its C-terminal region. Previously, we have shown the structural dynamics of the NSP1 C-terminal region (NSP1-CTR) in different physiological environments. So, it would be very interesting to investigate the druggable compounds that could…
Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 Mpro - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been causing the COVID-19 pandemic, resulting in several million deaths being reported. Numerous investigations have been carried out to discover a compound that can inhibit the biological activity of the SARS-CoV-2 main protease, which is an enzyme related to the viral replication. Among these, PF-07321332 (Nirmatrelvir) is currently under clinical trials for COVID-19 therapy. Therefore, in this work, atomistic and electronic…
Antiviral activities of natural compounds and ionic liquids to inhibit the Mpro of SARS-CoV-2: a computational approach - The recalcitrant spread of the COVID-19 pandemic produced by the novel coronavirus SARS-CoV-2 is one of the most destructive occurrences in history. Despite the availability of several effective vaccinations and their widespread use, this line of immunization often faces questions about its long-term efficacy. Since coronaviruses rapidly change, and multiple SARS-CoV-2 variants have emerged around the world. Therefore, finding a new target-based medication became a priority to prevent and…
Blocking key mutated hotspot residues in the RBD of the omicron variant (B.1.1.529) with medicinal compounds to disrupt the RBD-hACE2 complex using molecular screening and simulation approaches - A new variant of SARS-CoV-2 known as the omicron variant (B.1.1.529) reported in South Africa with 30 mutations in the whole spike protein, among which 15 mutations are in the receptor-binding domain, is continuously spreading exponentially around the world. The omicron variant is reported to be highly contagious with antibody-escaping activity. The emergence of antibody-escaping variants is alarming, and thus the quick discovery of small molecule inhibitors is needed. Hence, the current study…
Titanium dioxide and fluoropolymer-based coating for smart fabrics with antimicrobial and water-repellent properties - In the coronavirus disease 2019 pandemic, protective clothing is required for medical staff at risk of infection. This study proposes functional smart fabrics with antimicrobial and water-repellent properties, using titanium dioxide (TiO(2)) and fluoropolymer-based precursors as coating materials. Experimental results indicated a uniform distribution of TiO(2) particles with an average size below 200 nm throughout the fabric. A zone of inhibition test revealed that the fabric inhibited bacterial…
Identification of (2R,3R)-2-(3,4-dihydroxyphenyl)chroman-3-yl-3,4,5-trihydroxy benzoate as multiple inhibitors of SARS-CoV-2 targets; a systematic molecular modelling approach - Coronavirus disease of 2019 (COVID-19) is a zoonotic disease caused by a new severe acute respiratory syndrome (SARS- CoV-2) which has quickly resulted in a pandemic. Recent anti-COVID-19 drug discoveries are leaning towards repurposing phytochemicals which have been previously reported for SARS and MERS-CoV outbreaks. However, they have been either virtually screened or tested so far against mono targets and the potent derivatives of virtually sorted lead molecules remain elusive. We aimed to…
Flavonoids of Salvadora persica L. (meswak) and its liposomal formulation as a potential inhibitor of SARS- CoV-2 - Several studies are now underway as a worldwide response for the containment of the COVID-19 outbreak; unfortunately, none of them have resulted in an effective treatment. Salvadora persica L. (Salvadoraceae), commonly known as meswak, is one of the popular plants used by Muslims as an oral hygiene tool. It is documented that the meswak possesses antiviral activity, but no report discusses its use for coronavirus treatment. Herein, a mixture of 11 flavonoids prepared from the aqueous plant…
The inhibition of Mpro, the primary protease of COVID-19, by Poria cocos and its active compounds: a network pharmacology and molecular docking study - Poria cocos is a traditional Chinese medicine (TCM) that can clear dampness, promote diuresis, and strengthen the spleen and stomach. Poria cocos has been detected in many TCM compounds that are used for COVID-19 intervention. However, the active ingredients and mechanisms associated with the effect of Poria cocos on COVID-19 remain unclear. In this paper, the active ingredients of Poria cocos, along with their potential targets related to COVID-19, were screened using TCMSP, GeneCards, and…
Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study - The global breakout of COVID-19 and raised death toll has prompted scientists to develop novel drugs capable of inhibiting SARS-CoV-2. Conducting studies on repurposing some FDA-approved glucocorticoids can be a promising prospective for finding a treatment for COVID-19. In addition, the use of anti-inflammatory drugs, such as glucocorticoids, is a pivotal step in the treatment of critical cases of COVID-19, as they can provoke an inflammatory cytokine storm, damaging lungs. In this study, 22…
Translational Control of COVID-19 and Its Therapeutic Implication - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19, which has broken out worldwide for more than two years. However, due to limited treatment, new cases of infection are still rising. Therefore, there is an urgent need to understand the basic molecular biology of SARS-CoV-2 to control this virus. SARS- CoV-2 replication and spread depend on the recruitment of host ribosomes to translate viral messenger RNA (mRNA). To ensure the translation of their…
Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis - Recently published clinical data from COVID-19 patients indicated that statin therapy is associated with a better clinical outcome and a significant reduction in the risk of mortality. In this study by computational analysis, we have aimed to predict the possible mechanism of the statin group of drugs by which they can inhibit SARS-CoV-2 pathogenesis. Blind docking of the critical structural and functional proteins of SARS-CoV-2 like RNA-dependent RNA polymerase, M-protease of 3-CL-Pro,…
A Houttuynia Cordata-based Chinese herbal formula improved symptoms of allergic rhinitis during the COVID-19 pandemic - CONCLUSION: ZYF has potential effects to relieve nasal symptoms for AR during the COVID-19 pandemic.
Inhibition of endocytic recycling of ACE2 by SARS-CoV-2 S protein partially explains multiple COVID-19 related diseases caused by ACE2 reduction - No abstract
SYSTEM FOR MONITORING COVID-19 PATIENTS USING A VIRTUAL TELEPRESENCE ROBOT - Attached Separately - link
MACHINE LEARNING TECHNIQUE TO ANALYZE THE WORK PRESSURE OF PARAMEDICAL STAFF DURING COVID 19 - Machine learning technique to analyse the work pressure of paramedical staff during covid 19 is the proposed invention that focuses on identifying the stress levels of paramedical staff. The invention focuses on analysing the level of stress that is induced on the paramedical staff especially during pandemic. - link
基于SARS-CoV-2的S蛋白的疫苗及其用途 - 本公开提供了基于SARS‑CoV‑2的S蛋白的疫苗及其用途,并具体涉及重组SARS‑CoV‑2刺突蛋白(S蛋白)及编码其的mRNA和DNA。本公开还涉及包含编码重组S蛋白的DNA序列的重组质粒。本公开的重组质粒经转录得到mRNA,其包含SEQ ID NO.12所示的序列。本公开进一步涉及包含前述mRNA的mRNA‑载体颗粒例如脂质纳米颗粒(LNP)和组合物例如疫苗组合物。 - link
CBD Covid 19 Protection - - link
一种双价可电离脂质化合物、组合物及其应用 - 本发明涉及核酸药物递送技术领域,特别是关于一种双价可电离脂质化合物、组合物及其应用。本发明提供多种可以递送核酸药物的可电离阳离子脂质,具备较强的可设计性、可生物降解性及高效的体内外转染效率,由其组成的脂质纳米递送系统用于递送mRNA,在细胞水平上,优于目前上市的产品,并且在动物水平也具有良好的递送效率,可以作为核酸药物的递送新的方法,促进核酸药物的发展。 - link
一种双价可电离脂质化合物、组合物及其应用 - 本发明涉及核酸药物递送技术领域,特别是关于一种双价可电离脂质化合物、组合物及其应用。本发明提供多种可以递送核酸药物的可电离阳离子脂质,具备较强的可设计性、可生物降解性及高效的体内外转染效率,由其组成的脂质纳米递送系统用于递送mRNA,在细胞水平上,优于目前上市的产品,并且在动物水平也具有良好的递送效率,可以作为核酸药物的递送新的方法,促进核酸药物的发展。 - link
新冠肺炎CT图像分割方法及终端设备 - 本发明公开了一种新冠肺炎CT图像分割方法及终端设备,方法包括获取待分割新冠肺炎CT图像;将该图像输入至训练好的分割模型中,得到新冠肺炎病灶区域的图像;其中分割模型包括依次连接的多个下采样模块和下采样模块对应的上采样模块;每个采样模块均包括依次连接的第一提取单元和第二提取单元;上述两个提取单元的卷积模块均为结构重参数化卷积模块。本发明的结构重参数化卷积模块为训练时使用多分支结构,加强模型表达能力,推理时使用单路结构,加快推理速度,快速得出诊断结果。同时,为从不同尺度特征图中学习分层表示,加强模型对图像边缘信息提取,并使梯度更快回流,上采样每一侧输出都连接混合损失函数,实现图像的像素级分割。 - link
一种一步法核酸检测方法及其所用的密封性核酸检测装置 - 本发明涉及一种一步法核酸检测方法及其所用的密封性核酸检测装置,该密封性核酸检测装置,主体为PCR管,包括管盖、管体,管体内分为三层,最下层为PCR冻干试剂层,是将PCR冻干试剂密封在第一石蜡层中构成;中间层为盐酸溶液;最上层为核酸提取试剂层,核酸提取试剂层与盐酸溶液之间通过第二石蜡层隔离;核酸提取试剂层中放置核酸检测所需的一步法核酸提取试剂。本发明实现同一PCR管内的空间隔离,做到只需一次加样,即可完成PCR检测,无需中间繁琐的核酸提取过程和核酸加样操作,反应完成后,也无需开盖分析,核酸提取和检测过程做到真正的零污染,且整个过程操作简单,大大降低了检测成本。 - link
Vorrichtung (1) zur Aufnahme von Proben, insbesondere Speichelproben zum Nachweis von SARS-CoV-2 Virus im Speichel, mit
einer Probenentnahmeeinrichtung (8), die an einem ersten freien Ende (10) zumindest ein erstes Entnahmeelement (12) aufweist, mit dem die Probe entnehmbar ist, und wobei die Probenentnahmeeinrichtung (8) in den Aufnahmebehälter (2) einführbar ist, dadurch gekennzeichnet, dass die Probenentnahmeeinrichtung (8) an einem dem ersten freien Ende (10) gegenüberliegenden zweiten Ende (14) mit der Verschlusseinrichtung (6) verbunden ist, so dass die Probenentnahmeeinrichtung (8) mittels der Verschlusseinrichtung (6) in den Aufnahmebehälter (2) einführbar ist.